Physician profile
Ibrahim Qaqish
NPI 1740462431
$6,678.14
in general payments reported to CMS, 2019-2025
31 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $150 · 2021: $537 · 2022: $976 · 2023: $1,722 · 2024: $1,119 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,280 · Education: $66.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,280.40 |
| Education | $66.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $723.00 | 2020-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $658.13 | 2021-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $519.78 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $460.54 | 2023-2024 | |
| Novo Nordisk INC | $417.07 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $402.59 | 2022-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $371.94 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $357.63 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $291.02 | 2021-2025 | Livtencity |
| Novartis Pharmaceuticals Corporation | $218.24 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $209.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $208.77 | 2024-2025 | Prevymis, Zerbaxa |
| Veloxis Pharmaceuticals, INC. | $207.05 | 2022-2025 | Envarsus |
| Abbott Laboratories | $184.86 | 2019 | |
| Nxstage Medical, INC. | $158.48 | 2023 | Liberty Select Cycler, Nxstage System One |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $155.70 | 2020-2025 | Vafseo |
| Vifor Pharma, INC. | $139.14 | 2021 | |
| Mallinckrodt Enterprises LLC | $136.72 | 2019 | |
| Calliditas Therapeutics US INC. | $127.88 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $124.78 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $120.90 | 2025 | |
| Lilly USA, LLC | $119.05 | 2025 | |
| Glaxosmithkline, LLC. | $104.37 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $84.75 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $46.98 | 2021-2023 | Rayaldee |
| Janssen Pharmaceuticals, INC | $34.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.06 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $19.93 | 2025 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $19.29 | 2025 | Empaveli |
| Genentech USA, INC. | $18.64 | 2019 | |
| Allergan, INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Qaqish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.